Prostaglandin synthetase inhibition and formation of lipoxygenase products in immunologically challenged normal human lung parenchyma.
Normal human lung parenchyma, passively sensitized with an hyperimmune serum, releases eicosanoids from the cyclo-oxygenase pathway and from different lipoxygenases (5-, 12-, 15-HETE) upon anti-IgE challenge. Prostaglandin D2 represents almost 50% of the total arachidonate metabolites whereas, among sulphidopeptide leukotrienes, LTE4 is the one present in larger amounts. Pretreatment of the passively sensitized tissue with indomethacin (1.5 X 10(-5) M) inhibits cyclo-oxygenase by more than 90% without a concomitant shift of arachidonate metabolism towards leukotriene formation.
Vigano
T
T
Institute of Pharmacological Sciences, School of Pharmacy, University of Milan, Italy.
Toia
A
A
Crivellari
M T
MT
Galli
G
G
Mezzetti
M
M
Folco
G C
GC
D001681:Biological Assay; D002851:Chromatography, High Pressure Liquid; D016861:Cyclooxygenase Inhibitors; D006801:Humans; D007106:Immune Sera; D007124:Immunoenzyme Techniques; D007213:Indomethacin / Q000494:pharmacology; D015289:Leukotrienes / Q000378:metabolism; D008084:Lipoxygenase / Q000378:metabolism*; D008168:Lung / Q000201:enzymology / Q000276:immunology / Q000378:metabolism*; D015230:Prostaglandin D2 / Q000032:analysis; D012016:Reference Values; D013189:SRS-A / Q000032:analysis
D016861:Cyclooxygenase Inhibitors; D007106:Immune Sera; D015289:Leukotrienes; D013189:SRS-A; D008084:Lipoxygenase; D015230:Prostaglandin D2; D007213:Indomethacin